Slide 1: Immuron CEO presentation at Coffee Microcaps Conference
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference Melbourne, Australia, March 5, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March
Slide 2: For personal use only
are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits direc
Slide 3: IBS overview and references
Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected.
Slide 4: Steven Lydeamore, Chief Executive Officer
NASDAQ: IMRN ASX: IMC For personal use only Investor Presentation Steven Lydeamore Chief Executive Officer 5 March 2026
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 6: Immuron integrated biopharmaceutical company overview
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases For personal use only Technology Research & Technology Platform Development Global Corporate Platform Safe and pot
Slide 7: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview For personal use only Three commercial products: Travelan® (travele
Slide 8: Immuron strategic reset provides clearer path to profitability
Immuron strategic reset provides clearer path to profitability Immuron has taken a strategic decision to partner clinical assets IMM-124E and IMM-529 for development and commercialization. For personal use only • IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: trave
Slide 9: IMM-124E Market Potential
IMM-124EMarket Potential TAM (Total Addressable Market) The global Traveler’s Diarrhea (TD) market, including all treatments (antibiotics, anti-diarrhea agents) and prevention (vaccines, probiotics). • Global Value: The global Traveler's Diarrhea treatment market is estimated at For personal use onl
Slide 10: IMM-529 Market Potential
IMM-529 Market Potential The Disease: C. difficile is the leading cause of healthcare-associated For personal use only infection causing 400,000 cases and 30,000 deaths in the US annually Disease spectrum: • Mild-to-moderate: Watery persistent diarrhea, cramping • Severe/Pseudomembranous Colitis (PM
Slide 11: IMM-529 Deal Potential
IMM-529 Deal Potential Licensor / Asset Stage at Year Licensee / Acquirer Licensed Asset Financial terms (public) Status update (as of March 2026) Owner deal For personal use only Asset sale signed Aug 2024 (public reporting FDA approved (Apr 2023) and commercialized by VOWST (SER-109) indicates dea
Slide 12: Financial & Operational Highlights
For personal use only 1. FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 13: HY26 Financial Summary
HY26 Financial Summary North American For personal use only Global Sales Australian Sales Sales Revenue Revenue Revenue $0.9m $4.2m $3.3m Down1 18% Up 5% Up 13% USA Up 17% EBITDX (ex-R&D)2 Cash $10.0m Gross Profit $(1.1)m Up $7.2m3 on 30 Jun 25 Margin Up $0.1m ≈ 23.5 months cash4 63% Up $0.7m (calcu
Slide 14: Continued strong sales growth
Continued strong sales growth Global For personal use only + HY2026 AUD$4.2 million up 5% on prior year Australia + HY2026 AUD$3.3 million up 13% on prior year North America + HY2026 AUD$0.9 million down 18% on prior year + USA HY2026 AUD$0.9 million up 17% on prior year + Post HY, secured distribut
Slide 15: Commercial – Operational Highlights
Commercial – Operational Highlights 1H FY26 and 2H FY24 1H FY25 2H FY25 Outlook For personal use only Travelan® / Protectyn® • $2.55m global sales • $3.99m global sales • $3.29m global sales • $4.18m global sales Revenue • $1.87m Australia • $2.89m Australia • $2.36m Australia • $3.27m Australia • $
Slide 16: Steven Lydeamore contact information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172